Following a decline driven by an underwhelming outlook from its weight loss rival Novo Nordisk (NVO), Eli Lilly (LLY) added ~9% in the premarket on Wednesday after the Indiana-based pharma giant beat Street forecasts with its Q4 2025 financials and 2026 outlook.
The Zepbound maker reported $19.3B in revenue for the quarter, beating the consensus by as much as ~$1.4B with ~43% YoY growth, while its adjusted EPS of $7.54 indicated a ~42% YoY growth, beating the consensus by $0.61.
The company projected $33.50 – $35.00 of adjusted EPS on $80B – $83B in revenue compared to $24.21 of EPS and $61.2B in revenue for 2025. The forecast at the midpoint comfortably beat $33.60 and $77.56B in the consensus, respectively.
Novo Nordisk (NVO) plunged ~15% on Tuesday, dragging Lilly (LLY) after the Danish drugmaker projected a 5%-13% YoY decline in revenue on a forex-adjusted basis for 2026, citing, among other things, competition and upcoming patent cliffs for its blockbuster GLP-1 therapy semaglutide.